tiprankstipranks
Oxford BioMedica plc (GB:OXB)
LSE:OXB
UK Market
OXB
Oxford BioMedica
RESEARCH TOOLSreports
Want to see GB:OXB full AI Analyst Report?

Oxford BioMedica (OXB) Share Forecast & Price Target

112 Followers
See the Price Targets and Ratings of:

OXB Analyst Ratings

Moderate Buy
2Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
Based on 2 analysts giving stock ratings to
Oxford
BioMedica
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

998.50 p
▲(73.65% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 998.50 p with a high forecast of 1,170.00 p and a low forecast of 827.00 p. The average price target represents a 73.65% change from the last price of 575.00 p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"317":"317 p","744":"744 p","1171":"1,171 p","530.5":"530.5 p","957.5":"957.5 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.17K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":998.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">998.50 p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":827,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">827.00 p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[317,530.5,744,957.5,1171],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,616,658.6153846153846,701.2307692307693,743.8461538461538,786.4615384615385,829.0769230769231,871.6923076923076,914.3076923076923,956.9230769230769,999.5384615384615,1042.1538461538462,1084.7692307692307,1127.3846153846152,{"y":1170,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,616,645.4230769230769,674.8461538461538,704.2692307692307,733.6923076923077,763.1153846153846,792.5384615384615,821.9615384615385,851.3846153846154,880.8076923076924,910.2307692307693,939.6538461538462,969.0769230769231,{"y":998.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,616,632.2307692307693,648.4615384615385,664.6923076923077,680.9230769230769,697.1538461538462,713.3846153846154,729.6153846153846,745.8461538461538,762.0769230769231,778.3076923076923,794.5384615384615,810.7692307692307,{"y":827,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":328.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":464.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":590,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":657,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":618,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":617,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":830,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":645,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":593,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target1,170 pAverage Price Target998.50 pLowest Price Target827.00 p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on GB:OXB
Charles Weston
RBC Capital
RBC Capital
1,170 p
Buy
103.48%
Upside
Reiterated
06/03/26
RBC Capital Keeps Their Buy Rating on Oxford BioMedica (OXBDF)
Jefferies Analyst forecast on GB:OXB
James Vane
Jefferies
Jefferies
827 p
Buy
43.83%
Upside
Reiterated
06/02/26
Jefferies Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)
Stifel Nicolaus Analyst forecast on GB:OXB
James Orsborne
Stifel Nicolaus
Stifel Nicolaus
950 p
Buy
65.22%
Upside
Reiterated
03/11/26
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Oxford BioMedica (Other OTC: OXBDF)
Deutsche Bank Analyst forecast on GB:OXB
Kane Slutzkin
Deutsche Bank
Deutsche Bank
380 p→735 p
Buy
27.83%
Upside
Upgraded
01/06/26
Oxford Biomedica upgraded to Buy from Hold at Deutsche BankOxford Biomedica upgraded to Buy from Hold at Deutsche Bank
J.P. Morgan Analyst forecast on GB:OXB
Zain Ebrahim
J.P. Morgan
J.P. Morgan
400 p→550 p
Hold
-4.35%
Downside
Reiterated
12/08/25
Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan
Canaccord Genuity Analyst forecast on GB:OXB
Unknown Analyst
Canaccord Genuity
Not Ranked
Canaccord Genuity
451 p
Buy
-21.57%
Downside
Reiterated
10/07/25
Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity
Peel Hunt Analyst forecast on GB:OXB
Unknown Analyst
Peel Hunt
Not Ranked
Peel Hunt
451 p
Buy
-21.57%
Downside
Reiterated
08/01/25
Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on GB:OXB
Charles Weston
RBC Capital
RBC Capital
1,170 p
Buy
103.48%
Upside
Reiterated
06/03/26
RBC Capital Keeps Their Buy Rating on Oxford BioMedica (OXBDF)
Jefferies Analyst forecast on GB:OXB
James Vane
Jefferies
Jefferies
827 p
Buy
43.83%
Upside
Reiterated
06/02/26
Jefferies Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)
Stifel Nicolaus Analyst forecast on GB:OXB
James Orsborne
Stifel Nicolaus
Stifel Nicolaus
950 p
Buy
65.22%
Upside
Reiterated
03/11/26
Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Oxford BioMedica (Other OTC: OXBDF)
Deutsche Bank Analyst forecast on GB:OXB
Kane Slutzkin
Deutsche Bank
Deutsche Bank
380 p→735 p
Buy
27.83%
Upside
Upgraded
01/06/26
Oxford Biomedica upgraded to Buy from Hold at Deutsche BankOxford Biomedica upgraded to Buy from Hold at Deutsche Bank
J.P. Morgan Analyst forecast on GB:OXB
Zain Ebrahim
J.P. Morgan
J.P. Morgan
400 p→550 p
Hold
-4.35%
Downside
Reiterated
12/08/25
Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan
Canaccord Genuity Analyst forecast on GB:OXB
Unknown Analyst
Canaccord Genuity
Not Ranked
Canaccord Genuity
451 p
Buy
-21.57%
Downside
Reiterated
10/07/25
Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity
Peel Hunt Analyst forecast on GB:OXB
Unknown Analyst
Peel Hunt
Not Ranked
Peel Hunt
451 p
Buy
-21.57%
Downside
Reiterated
08/01/25
Peel Hunt Keeps Their Buy Rating on Oxford BioMedica (OXBDF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

3 Months
James OrsborneStifel Nicolaus
Success Rate
5/8 ratings generated profit
63%
Average Return
+19.36%
Copying James Orsborne's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +19.36% per trade.
1 Year
James OrsborneStifel Nicolaus
Success Rate
7/8 ratings generated profit
88%
Average Return
+58.79%
Copying James Orsborne's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +58.79% per trade.
2 Years
James OrsborneStifel Nicolaus
Success Rate
7/8 ratings generated profit
88%
Average Return
+77.15%
Copying James Orsborne's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +77.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXB Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
2
1
1
Buy
2
3
2
2
1
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
5
4
3
2
In the current month, OXB has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 998.50.
Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.24 p with a range of -0.24 p to -0.24 p. The previous quarter’s EPS was -0.05 p. OXB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.
Next quarter’s earnings estimate for OXB is -0.24 p with a range of -0.24 p to -0.24 p. The previous quarter’s EPS was -0.05 p. OXB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 98.10M with a range of 98.10M to 98.10M . The previous quarter’s sales results were 95.52M . OXB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.
Next quarter’s sales forecast for OXB is 98.10M with a range of 98.10M to 98.10M . The previous quarter’s sales results were 95.52M . OXB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?
Based on analyst ratings, Oxford BioMedica plc’s 12-month average price target is 998.50.
    What is GB:OXB’s upside potential, based on the analysts’ average price target?
    Oxford BioMedica plc has 73.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Oxford BioMedica plc a Buy, Sell or Hold?
          Oxford BioMedica plc has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Oxford BioMedica plc’s share price target?
            The average share price target for Oxford BioMedica plc is 998.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 1,170.00 p ,and the lowest forecast is 827.00 p. The average share price target represents 73.65% Increase from the current price of 575 p.
              What do analysts say about Oxford BioMedica plc?
              Oxford BioMedica plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
                How can I buy shares of Oxford BioMedica plc?
                To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.